These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 15116260)

  • 1. Pharmacogenetics of the CD14 endotoxin receptor polymorphism and progression of coronary atherosclerosis.
    Agema WR; Wouter Jukema J; de Maat MP; Zwinderman AH; Kastelein JJ; Rabelink TJ; van der Wall EE
    Thromb Haemost; 2004 May; 91(5):986-90. PubMed ID: 15116260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mannose binding lectin 2 haplotypes do not affect the progression of coronary atherosclerosis in men with proven coronary artery disease treated with pravastatin.
    Alipour A; Cabezas MC; Elte JW; Vallvé JC; Ribalta J; Zwinderman AH; Defesche JC; Jukema JW
    Atherosclerosis; 2011 Mar; 215(1):125-9. PubMed ID: 21211797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS).
    Klerkx AH; de Grooth GJ; Zwinderman AH; Jukema JW; Kuivenhoven JA; Kastelein JJ
    Eur J Clin Invest; 2004 Jan; 34(1):21-8. PubMed ID: 14984434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic variation in the rate-limiting enzyme in cholesterol catabolism (cholesterol 7alpha-hydroxylase) influences the progression of atherosclerosis and risk of new clinical events.
    Hofman MK; Princen HM; Zwinderman AH; Jukema JW
    Clin Sci (Lond); 2005 Jun; 108(6):539-45. PubMed ID: 15707388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events.
    Boekholdt SM; Agema WR; Peters RJ; Zwinderman AH; van der Wall EE; Reitsma PH; Kastelein JJ; Jukema JW;
    Circulation; 2003 May; 107(19):2416-21. PubMed ID: 12742999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Association of C-159T polymorphism in promoter region of CD14 and coronary heart disease].
    Li Y; Xiong XQ; Zhang PA; Ming KH
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Dec; 22(6):687-90. PubMed ID: 16331574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD14 gene polymorphism 159C/T in a group of patients with coronary artery disease from a population with high morbidity of cardiovascular diseases.
    Rechciński T; Grebowska A; Kurpesa M; Peruga Z; Dziuba M; Krzemińska-Pakuła M; Rudnicka W; Chmiela M
    Kardiol Pol; 2007 Mar; 65(3):237-44; discussion 245. PubMed ID: 17436151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD14 expression on monocytes and soluble CD14 plasma levels in correlation to the promotor polymorphism of the endotoxin receptor CD14 gene in patients with inactive Crohn's disease.
    Griga T; Klein W; Epplen JT; Hebler U; Stachon A; May B
    Hepatogastroenterology; 2005; 52(63):808-11. PubMed ID: 15966209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of the CD14 C260T promoter polymorphism on C-reactive protein levels in patients with coronary artery disease.
    Bernardo E; Angiolillo DJ; Ramírez C; Cavallari U; Trabetti E; Sabaté M; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Pignatti PF; Macaya C; Fernandez-Ortiz A
    Am J Cardiol; 2006 Nov; 98(9):1182-4. PubMed ID: 17056323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: final 5-year angiographic follow-up of the Prevention of Coronary Sclerosis (PCS) study.
    Nakagawa T; Kobayashi T; Awata N; Sato S; Reiber JH; Nakajima H; Toyama YN; Hiraoka H; Kato O; Kirino M; Kobayashi T; Takeda Y; Yachiku K; Iida M; Itoh T; Shibata N
    Int J Cardiol; 2004 Oct; 97(1):107-14. PubMed ID: 15336816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD14 promoter polymorphism (- 159C-->t) is not associated with myocardial infarction or coronary artery disease in patients with assumed high genetic risk.
    Haberbosch W; Unkelbach K; Schuster D; Gardemann A; Tillmanns H; Hölschermann H
    Thorac Cardiovasc Surg; 2009 Oct; 57(7):386-90. PubMed ID: 19795323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of the -159C/T polymorphism of the endotoxin receptor (CD14) with carotid artery disease and cardiovascular mortality in dialysis patients.
    Losito A; Kalidas K; Santoni S; Errico R; Jeffery S
    Blood Purif; 2005; 23(2):128-33. PubMed ID: 15640605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. -455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group.
    de Maat MP; Kastelein JJ; Jukema JW; Zwinderman AH; Jansen H; Groenemeier B; Bruschke AV; Kluft C
    Arterioscler Thromb Vasc Biol; 1998 Feb; 18(2):265-71. PubMed ID: 9484992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD14 C(-260)T promoter polymorphism and prevalence of acute coronary syndromes.
    Arroyo-Espliguero R; El-Sharnouby K; Vázquez-Rey E; Kalidas K; Jeffery S; Kaski JC
    Int J Cardiol; 2005 Feb; 98(2):307-12. PubMed ID: 15686783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A polymorphism in the promoter of the CD14 gene (CD14/-159) is associated with the development of coronary artery lesions in patients with Kawasaki disease.
    Nishimura S; Zaitsu M; Hara M; Yokota G; Watanabe M; Ueda Y; Imayoshi M; Ishii E; Tasaki H; Hamasaki Y
    J Pediatr; 2003 Sep; 143(3):357-62. PubMed ID: 14517520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter polymorphism of the CD14 endotoxin receptor gene is associated with biliary atresia and idiopathic neonatal cholestasis.
    Shih HH; Lin TM; Chuang JH; Eng HL; Juo SH; Huang FC; Chen CL; Chen HL
    Pediatrics; 2005 Aug; 116(2):437-41. PubMed ID: 16061600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group.
    Kuivenhoven JA; Jukema JW; Zwinderman AH; de Knijff P; McPherson R; Bruschke AV; Lie KI; Kastelein JJ
    N Engl J Med; 1998 Jan; 338(2):86-93. PubMed ID: 9420339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The C(-260)>T gene polymorphism in the promoter of the CD14 monocyte receptor gene is not associated with acute myocardial infarction.
    Longobardo MT; Cefalù AB; Pezzino F; Noto D; Emmanuele G; Barbagallo CM; Fiore B; Monastero R; Castello A; Molini V; Notarbartolo A; Travali S; Averna MR
    Clin Exp Med; 2003 Nov; 3(3):161-5. PubMed ID: 14648231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C(-260)T polymorphism in the promoter of CD 14 gene is not associated with myocardial infarction in the Tunisian population.
    Sediri Y; Hammami S; Kallel A; Mourali MS; Feki M; Elasmi M; Haj-Taieb S; Omar S; Sanhaji H; Mechmeche R; Jemaa R; Kaabachi N
    Exp Mol Pathol; 2011 Jun; 90(3):276-9. PubMed ID: 21333644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.